284 related articles for article (PubMed ID: 26215701)
21. Over expression of HIF1α is associated with inactivation of both LimD1 and VHL in renal cell carcinoma: Clinical importance.
Sur S; Maurya AK; Roy A; Sharp TV; Pal DK; Panda CK
Pathol Res Pract; 2017 Dec; 213(12):1477-1481. PubMed ID: 29033184
[TBL] [Abstract][Full Text] [Related]
22. HIF-1 mediates the Warburg effect in clear cell renal carcinoma.
Semenza GL
J Bioenerg Biomembr; 2007 Jun; 39(3):231-4. PubMed ID: 17551816
[TBL] [Abstract][Full Text] [Related]
23. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
24. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2.
Kurban G; Duplan E; Ramlal N; Hudon V; Sado Y; Ninomiya Y; Pause A
Oncogene; 2008 Feb; 27(7):1004-12. PubMed ID: 17700531
[TBL] [Abstract][Full Text] [Related]
25. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
26. pVHL mediates K63-linked ubiquitination of nCLU.
Xue J; Lv DD; Jiao S; Zhao W; Li X; Sun H; Yan B; Fan L; Hu RG; Fang J
PLoS One; 2012; 7(4):e35848. PubMed ID: 22532874
[TBL] [Abstract][Full Text] [Related]
27. Src activates HIF-1α not through direct phosphorylation of HIF-1α specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway.
Lee HY; Lee T; Lee N; Yang EG; Lee C; Lee J; Moon EY; Ha J; Park H
Carcinogenesis; 2011 May; 32(5):703-12. PubMed ID: 21335603
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
An J; Rettig MB
Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
[TBL] [Abstract][Full Text] [Related]
29. Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation.
Khacho M; Lee S
Future Oncol; 2009 Feb; 5(1):85-95. PubMed ID: 19243301
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide donor, (+/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1alpha by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation.
Park YK; Ahn DR; Oh M; Lee T; Yang EG; Son M; Park H
Mol Pharmacol; 2008 Jul; 74(1):236-45. PubMed ID: 18426857
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
32. The VHL short variant involves in protein quality control.
Liu Y; Yang H; Zuo F; Chen L
Gene; 2016 Sep; 589(1):63-71. PubMed ID: 27196060
[TBL] [Abstract][Full Text] [Related]
33. RhoBTB3 interacts with the 5-HT7a receptor and inhibits its proteasomal degradation.
Matthys A; Van Craenenbroeck K; Lintermans B; Haegeman G; Vanhoenacker P
Cell Signal; 2012 May; 24(5):1053-63. PubMed ID: 22245496
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
[TBL] [Abstract][Full Text] [Related]
35. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
[TBL] [Abstract][Full Text] [Related]
36. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line.
Lee K; Kang JE; Park SK; Jin Y; Chung KS; Kim HM; Lee K; Kang MR; Lee MK; Song KB; Yang EG; Lee JJ; Won M
Biochem Pharmacol; 2010 Oct; 80(7):982-9. PubMed ID: 20599784
[TBL] [Abstract][Full Text] [Related]
37. WSB1 promotes tumor metastasis by inducing pVHL degradation.
Kim JJ; Lee SB; Jang J; Yi SY; Kim SH; Han SA; Lee JM; Tong SY; Vincelette ND; Gao B; Yin P; Evans D; Choi DW; Qin B; Liu T; Zhang H; Deng M; Jen J; Zhang J; Wang L; Lou Z
Genes Dev; 2015 Nov; 29(21):2244-57. PubMed ID: 26545811
[TBL] [Abstract][Full Text] [Related]
38. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors.
Warnecke C; Griethe W; Weidemann A; Jürgensen JS; Willam C; Bachmann S; Ivashchenko Y; Wagner I; Frei U; Wiesener M; Eckardt KU
FASEB J; 2003 Jun; 17(9):1186-8. PubMed ID: 12709400
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL.
Hasanov E; Chen G; Chowdhury P; Weldon J; Ding Z; Jonasch E; Sen S; Walker CL; Dere R
Oncogene; 2017 Jun; 36(24):3450-3463. PubMed ID: 28114281
[TBL] [Abstract][Full Text] [Related]
40. In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: a new player in the VHL/HIF-1α interaction pathway?
Minervini G; Masiero A; Moro S; Tosatto SC
FEBS Lett; 2013 Sep; 587(18):2996-3001. PubMed ID: 23886708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
